Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation

Table 4 Univariate analysis of tumor recurrence-free 1-, 3- and 5-year survival rates post-liver transplantation between patients with diabetes mellitus and without diabetes mellitus

Variables	DM, %			Non-DM, %			P value
	1 yr	3 yr	5 yr	1 yr	3 yr	5 yr
Sex
Male	73	69	67	77	71	69	0.204
Female	76	63	63	83	82	80	0.110
Age, yr
≤ 50	73	68	68	73	69	67	0.940
> 50	73	69	66	81	75	73	0.015
Tumor size, in cm
≤ 3	78	75	75	85	81	79	0.076
3-5	82	75	71	80	73	71	0.823
5-7	52	43	31	58	54	53	0.174
> 7	31	25	25	47	39	39	0.087
Number of tumor nodules
Single	81	77	75	83	79	77	0.475
2-3	67	64	64	79	75	73	0.031
≥ 4	64	57	55	63	55	53	0.825
Venous invasion
Absent	80	76	74	82	78	76	0.301
Present	28	22	19	48	37	35	0.005
Lymph node invasion
Absent	74	69	67	78	73	71	0.058
Present	64	64	64	67	59	55	0.580
Capsular invasion
Absent	75	71	69	78	73	71	0.201
Present	60	55	55	69	67	62	0.192
Microsatellite lesions
Absent	79	74	72	80	75	73	0.542
Present	52	49	46	63	60	58	0.039
Edmonton
1	91	91	91	100	100	100	0.134
2	77	73	72	80	74	72	0.375
3 + 4 + 5	67	59	57	72	67	66	0.175
Serum AFP level, in ng/mL
< 200	80	76	75	82	78	76	0.272
200-400	59	59	59	72	63	62	0.484
400-1000	65	46	37	77	65	63	0.251
1000-2000	61	43	43	62	55	49	0.682
> 2000	17	17	17	44	42	39	0.055
MELD score
< 10	68	60	58	75	69	67	0.058
10-15	72	70	70	78	73	70	0.412
> 15	79	76	72	79	76	74	0.534
Child-Pugh class
A	75	71	69	78	72	70	0.672
B	69	65	61	77	72	70	0.052
C	76	71	71	76	73	71	0.610
Fasting blood glucose, in mmol/L
≤ 7	72	68	67	77	72	70	0.154
> 7	74	69	67	70	68	63	0.914
BMI, in kg/m2
< 18.5	63	57	57	80	72	69	0.223
18.5-24	73	70	68	77	72	70	0.216
24-28	76	69	69	78	73	71	0.524
> 28	77	69	63	76	71	67	0.774
ALP, in IU/L
≤ 112	80	75	73	81	75	73	0.747
> 112	63	60	57	71	67	65	0.056
GGT, in IU/L
≤ 54	85	84	82	87	82	80	0.957
> 54	67	60	58	70	65	63	0.101
AST, in IU/L
≤ 40	81	76	73	84	79	78	0.201
40-80	69	65	65	78	72	70	0.103
> 80	70	65	62	66	61	58	0.767
ALT, in IU/L
≤ 40	79	76	75	82	79	77	0.318
40-80	68	63	60	77	70	68	0.033
> 80	72	65	64	65	60	58	0.376
TC, in mmol/L
≤ 1.7	74	69	67	78	73	71	0.113
> 1.7	71	68	65	66	63	60	0.894
CH, in mmol/L
< 3.88	75	70	68	78	74	72	0.175
3.88-5.2	68	66	64	79	72	71	0.092
> 5.2	76	68	68	66	60	57	0.415
Pre-LT antitumor therapy
No	73	68	67	78	72	70	0.061
local therapy	68	66	66	70	67	64	0.939
Resection	81	77	70	83	79	76	0.758
HBeAg
Negative	72	69	66	78	71	70	0.095
Positive	77	69	69	75	74	71	0.633
HBV-DNA, in × 103 IU/mL
< 1	75	69	68	78	74	72	0.165
> 1	71	68	65	76	70	67	0.256
Post-LT HBsAg reinfection
Negative	73	69	67	77	73	70	0.092
Positive	70	60	60	72	60	58	0.899

BMI: Body mass index; DM: Diabetes mellitus; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transpeptidase; TG: Triglyceride; CH: Cholesterol; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; LT: Liver transplantation.